Immunotoxin pharmacokinetics: A comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13

Journal of Neuro-Oncology

Volumn 77, Issue 3, 2006, Pages 257-266

  Rustamzadeh, Edward ^a,b   Vallera, Daniel A ^a   Todhunter, Deborah A ^a   Low, Walter C ^a   Panoskaltsis Mortari, Angela ^a   Hall, Walter A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Brain; Diphtheria toxin; Glioblastoma; IL 13; urokinase; Immunotoxin; Mouse; Pharmacokinetics

Indexed keywords

AMINO TERMINAL UROKINASE DIPHTHERIA IMMUNOTOXIN FUSION PROTEIN; AMINO TERMINAL UROKINASE DIPHTHERIA IMMUNOTOXIN INTERLEUKIN 13 FUSION PROTEIN; ANTINEOPLASTIC AGENT; DIPHTHERIA IMMUNOTOXIN INTERLEUKIN 13 FUSION PROTEIN; DIPHTHERIA TOXIN; IMMUNOTOXIN; INDIUM CHLORIDE IN 111; INTERLEUKIN 13 RECEPTOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; DIPHTHERIA TOXIN UROKINASE FUSION PROTEIN, HUMAN; DIPHTHERIA TOXIN-UROKINASE FUSION PROTEIN, HUMAN; HYBRID PROTEIN; INTERLEUKIN 13; UROKINASE;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CANCER CELL CULTURE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; HEMISPHERE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; ISOTOPE LABELING; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN SYNTHESIS INHIBITION; TISSUE DISTRIBUTION; ANIMAL; BRAIN; C57BL MOUSE; DRUG EFFECT; IMMUNOLOGY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PROTEIN SYNTHESIS; VASCULARIZATION;

ANIMALS; BRAIN; DIPHTHERIA TOXIN; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOTOXINS; INTERLEUKIN-13; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN BIOSYNTHESIS; RECOMBINANT FUSION PROTEINS; URINARY PLASMINOGEN ACTIVATOR;

EID: 33748413376     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-005-9051-7     Document Type: Article

References (48)

1. Todhunter DA, Hall WA, Rustamzadeh E, Shu Y, Doumbia SO, Vallera DA (2004) A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model Protein Eng Des Sel 17: 157-164
2. Salcman M, (1985) The morbidity and mortality of brain tumors. A perspective on recent advances in therapy Neurol Clin 3: 229-257
3. Frankel SA, German WJ (1958) Glioblastoma multiforme (review of 219 cases with regard to natural history, pathology, diagnostic methods and treatment) J Neurosurg 15: 489-503
4. Walker AE, Robins M, Weinfeld FD (1985) Epidemiology of brain tumors: the national survey of intracranial neoplasms Neurology 35: 219-226
5. Mahaley MS, Mettlin C, Natarajan N, Laws ER Jr, Peace BB (1989) National survey patterns of care for brain tumor patients J Neurosurg 71: 826-836
6. Rustamzadeh E, Low WC, Vallera DA, Hall WA (2003) Immunotoxin therapy for CNS tumor J Neurooncol 64: 101-116
7. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK (2000) Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma Clin Cancer Res 6: 2157-2165
8. Kawakami M, Kawakami K, Puri RK (2003) Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy J Neurooncol 65: 15-25
9. Li C, Hall WA, Jin N, Todhunter DA, Panoskaltsis-Mortari A, Vallera DA (2002) Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice Protein Eng 15: 419-427
10. Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY (1999) Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas Clin Cancer Res 5: 985-990
11. Debinski W, Gibo DM, Slagle B, Powers SK, Gillespie GY (1999) Receptor for interleukin 13 is abundantly and specifically overexpressed in patients with glioblastoma multiforme Int J Oncol 15: 481-486
12. Mintz A, Gibo DM, Madhankumar AB, Debinski W (2003) Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma J Neurooncol 64: 117-123
13. Husain SR, Joshi BH, Puri RK (2001) Interleukin-13 receptor as a unique target for anti-glioblastoma therapy Int J Cancer 92: 168-175
14. Vallera DA, Li C, Jin N, Panoskaltsis-Mortari A, Hall WA (2002) Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT J Natl Cancer Inst 94: 597-606
15. Bu X, Khankaldyyan V, Gonzales-Gomez I, Groshen S, Ye W, Zhuo S, Pons J, Stratton JR, Rosenberg S, Laug WE (2004) Species-specific urokinase receptor ligands reduce glioma growth and increase survival primarily by antiangiogenesis mechanism Lab Invest 84:667-678
16. Stragliotto G, Vega F, Stasiecki P, Gropp P, Poisson M, Delattre JY (1996) Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD55900) in patients with recurrent malignant gliomas Eur J Cancer 32: 636-640
17. Brady LW, Miyamoto C, Woo DV, Rackover M, Emrich J, Bender H, Dadparvar S, Steplewski Z, Koprowski H, Black P (1992) Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody-425 against epidermal growth factor receptor: A phase II trialInt J Radiat Oncol Biol Phys 22:225-230
18. Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao XG, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE 2nd, Provenzale JM, Zalutsky MR, Bigner DD (2000) Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas J Clin Oncol 18: 3862-3872
19. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD (2002) Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas J Clin Oncol 20:1389-1397
20. Recht LD, Griffin TW, Raso V, Salimi AR (1990) Potent cytotoxicity of an antihuman transferring-ricin-A-chain immunotoxin human glioma cells in vitro Cancer Res 50: 6696-6700
21. Liu TF, Tatter SB, Willingham MC, Yang M, Hu JJ, Frankel AE (2003) Growth factor receptor expression varies among high-grade gliomas and normal brain: Epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy Mol Cancer Ther 2: 783-787
22. Wen DY, Hall WA, Conrad J, Godal A, Florenes VA, Fodstad O (1995) In vitro and in vivo variation in transferrin receptor expression on a human medulloblastoma cell line Neurosurgery 36: 1158-1163
23. Jain RK (1989) Delivery of novel therapeutic agents in tumors: physiological barriers and strategies J Natl Cancer Inst 81: 570-576
24. Dykes PW, Bradwell AR, Chapman CE, Vaughan AT (1987) Radioimmunotherapy of cancer: Clinical studies and limiting factors Cancer Treat Rev 14: 87-106
25. Yokota T, Milenic DE, Whitlow M, Schlom J (1992) Rapid tumor penetration of single chain Fv and comparison with other immunoglobulin forms Cancer Res 52: 3402-3408
26. Kennel SJ, Falcioni R, Wesley JW (1991) Microdistribution of specific rat monoclonal antibodies to mouse tissues and human tumor xenografts Cancer Res 51: 1529-1536
27. Kemshead JT, Hopkins K, Pizer B, Papanastassiou V, Coakham H, Bullimore J,Chandler C (1998) Dose escalation with repeated intrathecal injections of 131I-lablelled MAbs for the treatment of central nervous system malignancies Br J Cancer 77: 2324-2330
28. Riva P, Franceschi G, Arista A, Frattarelli M, Riva N, Cremonini AM, Giuliani G, Casi M (1997) Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: A six-year clinical experience Cancer 80: 2733-2742
29. Gondi CS, Lakka SS, Yanamandra N, Olivero WC, Dinh DH, Gujrati M, Tung CH, Weissleder R, Rao JS (2004) Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas Cancer Res 64: 4069-4077
30. Le DM, Besson A, Fogg DK, Choi KS, Waisman DM, Goodyer CG, Rewcastle B, Yong VW (2003) Exploitation of astrocytes by glioma cells to facilitate invasiveness: A mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade J Neurosci 23: 4034-4043
31. Lakka SS, Gondi CS, Yanamandra N, Dinh DH, Olivero WC, Gujrati M, Rao JS (2003) Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB 19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth Cancer Res 63: 2454-2461
32. Brechbiel MW, Beitzel PM, Gansow OA (1997) Purification of p-nitor-benzyl C-functionalized diethylenetriamine pentaacetic acids for clinical application using anion-exchange chromatography J Chromatogr 771: 63-69
33. Brechbiel MW, Gansow OA (1991) Backbone-substituted DTPA-ligands for 90 Y radioimmunotherapy Bioconjug Chem 2: 187-194
34. Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M (1984) Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions Anal Biochem 142: 68-78
35. Blazar BR, Taylor PA, Vallera DA (1994) In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice J Immunol 152: 3665-3674
36. Kuan CT, Reist CJ, Foulon CF, Lorimer IA, Archer G, Pegram CN, Pastan I, Zalutsky MR, Bigner DD (1999) 125 I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts Clin Cancer Res 5: 1539-1549
37. Kawakami K, Kawakami M, Kioi M, Husain SR, Puri RK (2004) Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in murine model J Neurosurg 101: 1004-1011
38. Yang W, Barth RF, Wu G, Ciesielski MJ, Fenstermaker RA, Moffat BA, Ross BD, Wikstrand CJ (2005) Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4 Clin Cancer Res 11: 341-350
39. Yang W, Barth RF, Adams DM, Ciesielski MJ, Fenstermaker RA, Shukla S, Tjarks W, Caligiuri MA (2002) Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas Cancer Res 62: 6552-6558
40. Kataoka K, Asai T, Taneda M, Ueshima S, Matsuo O, Kuroda R, Kawabata A, Carmeliet P (2000) Roles of urokinase type plasminogen activator in brain stab wound Brain Res 887: 187-190
41. Masos T, Miskin R (1996) Localization of urokinase-type plasminogen activator mRNA in the adult mouse brain Brain Res Mol Brain Res 35: 139-148
42. Cash E, Minty A, Ferrara P, Caput D, Fradelizi D, Rott O (1994) Macrophage-inactivating IL-13 suppresses experimental autoimmune encephalomyelitis in rats J Immunol 153: 4258-4267
43. Sebire G, Delfraissy JF, Demotes-Mainard J, Oteifeh A, Emilie D, Tardieu M (1996) Interleukin-13 and interleukin-4 act as interleukin-6 inducers in human microglial cells Cytokine 8: 636-641
44. Doolittle ND, Abrey LE, Ferrari N, Hall WA, Laws ER, McLendon RE, Muldoon LL, Peereboom D, Peterson DR, Reynolds CP, Senter P, Neuwelt EA (2002) Targeted delivery in primary and metastatic brain tumors: Summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium Clin Cancer Res 8: 1702-1709
45. Remsen LG, Trail PA, Hellstrom I, Neuwelt EA (2000) Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model Neurosurgery 46: 704-709
46. Neuwelt EA, Barnett PA, McCormick CI, Remsen LG, Kroll RA, Sexton G (1998) Differential permeability of a human brain tumor xenograft in the nude rat: Impact of tumor size and method of administration on optimizing delivery of biologically diverse agentsClin Cancer Res 4:1549-1555
47. Kroll RA, Pagel MA, Muldoon LL, Roman-Goldstein S, Fiamengo SA, Neuwelt EA (1998) Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: A comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers Neurosurgery 43: 879-886
48. Kroll RA, Pagel MA, Muldoon LL, Roman-Goldstein S, Neuwelt EA (1996) Increasing volume of distribution to the brain interstial infusion, dose rather than convection, might be the most important factor Neurosurgery 38: 746-752